MedicineOncologySurgeryCancer EpidemiologyEpidemiologic MethodsGastrointestinal OncologyCancer IncidenceCancer Survival AnalysisEndocrine Tumor PrognosisMalignant NeoplasmsMalignant TumorsNeuroendocrine TumorsAnnual IncidenceColonic AdenocarcinomaIncidence Trend AnalysisKaplan-meier Confidence IntervalsPrognostic Factors AnalysisSurvival RatesTemporal Trends In IncidenceTumor Incidence Analysis
BACKGROUND: Appendiceal tumors are considered to be a relatively rare tumor of the gastrointestinal tract and the prognosis is unclear. This study comprehensively investigated trends in the epidemiology and survival of appendiceal tumors in the United States over the past approximately 20 years. METHODS: Patients with pathologically confirmed appendiceal tumors from 2000 to 2017 were selected from the Surveillance, Epidemiology and End Results (SEER) database. Age-adjusted incidence rates were calculated by SEER*Stat 8.4.0. The Kaplan-Meier method was used to analyze survival and prognostic factors were investigated by a multivariate Cox proportional risk model. RESULTS: Ultimately, 13,546 patients with appendiceal tumors between 2000 and 2017 were included. The annual incidence of colonic adenocarcinoma and mucinous adenocarcinoma remained relatively stable. Interestingly, the annual incidence of appendiceal neuroendocrine tumors (aNETs) increased significantly, from 0.03 to 0.90 per 100,000 person-years, with the most dramatic increase in the number of patients with localized disease. Patients with aNETs showed a significant improvement in survival between 2009-2017, compared to the period 2000-2008. Moreover, this improvement in survival over time was seen at all stages (localized, regional, distant) of aNETs. However, this improved survival over time was not seen in colonic and mucinous adenocarcinoma. CONCLUSIONS: The incidence of appendiceal neoplasms has increased significantly over the past nearly two decades, which is mainly due to the increased incidence and significant migration to earlier stages in aNETs. We must note that despite the increased incidence of aNETs, survival rates have improved at different disease stages.
17
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle et al. · CA A Cancer Journal for Clinicians · 2023 · 16.7K citations · Full text
Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations
Medicine, Oncology, Pharmacotherapy +17
Marianne Pavel, John D. Hainsworth, Éric Baudin et al. · The Lancet · 2011 · 1.1K citations
Medicine, Oncology, Pharmacotherapy +16